Allcbdoilbenefits.com released the updated list of best pain relief oils for 2018

Blogger Aaron with allcbdoilbenefits.com compiled his annual list of the CBD oils that best help to control pain.What is CBD hemp oil and how...

A U.S. Food and Drug Administration (FDA) review to date has not identified adverse...

A U.S. Food and Drug Administration (FDA) review to date has not identified adverse health effects from gadolinium retained in the brain after the...

Rapper Nas Salutes Women with Multiple Sclerosis

*Los Angeles, CA | In support of the forthcoming September 2017 launch event and multiple sclerosis campaign for women of color, legendary hip-hop artist,...

Mallinckrodt Acthar Gel phase IV clinical study with relapsing multiple sclerosis

STAINES-UPON-THAMES, United Kingdom Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4...

Novartis multiple sclerosis drug Gilenya shows siginificant effect against pediatric MS in phase III...

Novartis MS Drug Gilenya shows siginificant effect in phase III trial: Against Pediatric MSNovartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect...

Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

SOURCE Novartis- Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions- In a pivotal Phase III study, oral fingolimod...
video

Allen Bowling, MD, PhD, talks about multiple sclerosis, marijuana and other unconventional therapies

Allen Bowling, MD, PhD, talks about multiple sclerosis clinicians' limited training in unconventional therapy at the Consortium of Multiple Sclerosis Centers (CMSC) 2017.

Celgene announces data on its phase III relapsing MS Ozanimod experimental treatment

Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN)...

New Inroads Against Multiple Sclerosis

JAMA recently published their interviews with two MS Specaists focusing on the medical progress against multiple sclerosis (MS) in 2017 with the approval by the...

Social Media

712FollowersFollow